We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Oncology

Journal Scan / Research · June 27, 2013

Durable Remissions Achieved With BTK Inhibitor Ibrutinib in Relapsed CLL

The New England Journal of Medicine


Additional Info

The New England Journal of Medicine
Targeting BTK With Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
N. Engl. J. Med 2013 Jun 19;[EPub Ahead of Print], JC Byrd, RR Furman, SE Coutre, IW Flinn, JA Burger, KA Blum, B Grant, JP Sharman, M Coleman, WG Wierda, JA Jones, W Zhao, NA Heerema, AJ Johnson, J Sukbuntherng, BY Chang, F Clow, E Hedrick, JJ Buggy, DF James, S O'Brien

Further Reading